The Europe Antibiotics Market would witness market growth of 4.9% CAGR during the forecast period (2020-2026). The rising case of bloodstream infections, pneumonia, and Urinary Tract Infections (UTI) is expected to boost the usage of carbapenems class of antibiotics. The increasing threat of drug-resistance is the key factor for the development of advanced combinational formulations. For example, the advent of multi-resistance tuberculosis and infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) is hard to cure with antibiotics, thus, the development of advanced antibiotics is needed.
Moreover, favorable government regulations like the Generating Antibiotics Incentives Now (GAIN) Act are estimated to speed up the approval process. GAIN Act has some provisions that help in the development of therapies against antibiotic-resistant pathogens. The major cause of death among children around the world is Diarrhea and it needs antibiotic intervention to stop the morbidity. Some other infectious diseases that created a high burden are pneumonia, HIV/AIDS, tuberculosis, and malaria. Apart from that, the birth of new infections, like the Zika and Ebola virus, are also assisting in the development and uptake of antibiotics.
The rising numbers of patients who are suffering from infectious diseases lead to the growth of the antibiotics market. Many pharmaceuticals companies are conducting on-going trials that are likely to propel the growth of the market. Additionally, advancement in antibiotics drugs and novel combination therapies to cure antibiotic-resistant microbial infections will improve the treatment scope, thereby driving the growth of the antibiotic market during the forecast period. Moreover, the special designation from the regulatory authority to several capable pharmaceutical companies, is the factor that further boosts the market growth.
Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: Antibiotics Market in Europe is expected to register a CAGR of 4.9% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.
Scope of the Study
Market Segments Covered in the Report:
By Action Mechanism
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- DNA Synthesis Inhibitors
- RNA Synthesis Inhibitors,
- Mycolic Acid Inhibitors
By Drug Class
- Cephalosporin
- Penicillin
- Fluoroquinolone
- Macrolides
- Carbapenem
- Aminoglycosides
- Sulfonamides,
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Johnson and Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Company
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Antibiotics Market, by Action Mechanism
1.4.2 Europe Antibiotics Market, by Drug Class
1.4.3 Europe Antibiotics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals
3.2.4 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct – 2020, Jul) Leading Players
Chapter 4. Europe Antibiotics Market by Action Mechanism
4.1 Europe Cell Wall Synthesis Inhibitors Market by Country
4.2 Europe Protein Synthesis Inhibitors Market by Country
4.3 Europe DNA Synthesis Inhibitors Market by Country
4.4 Europe RNA Synthesis Inhibitors Market by Country
4.5 Europe Others Market by Country
Chapter 5. Europe Antibiotics Market by Drug Class
5.1 Europe Cephalosporin Market by Country
5.2 Europe Penicillin Market by Country
5.3 Europe Fluoroquinolone Market by Country
5.4 Europe Macrolides Market by Country
5.5 Europe Carbapenem Market by Country
5.6 Europe Aminoglycosides Market by Country
5.7 Europe Sulfonamides Market by Country
5.8 Europe Others Market by Country
Chapter 6. Europe Antibiotics Market by Country
6.1 Germany Antibiotics Market
6.1.1 Germany Antibiotics Market by Action Mechanism
6.1.2 Germany Antibiotics Market by Drug Class
6.2 UK Antibiotics Market
6.2.1 UK Antibiotics Market by Action Mechanism
6.2.2 UK Antibiotics Market by Drug Class
6.3 France Antibiotics Market
6.3.1 France Antibiotics Market by Action Mechanism
6.3.2 France Antibiotics Market by Drug Class
6.4 Russia Antibiotics Market
6.4.1 Russia Antibiotics Market by Action Mechanism
6.4.2 Russia Antibiotics Market by Drug Class
6.5 Spain Antibiotics Market
6.5.1 Spain Antibiotics Market by Action Mechanism
6.5.2 Spain Antibiotics Market by Drug Class
6.6 Italy Antibiotics Market
6.6.1 Italy Antibiotics Market by Action Mechanism
6.6.2 Italy Antibiotics Market by Drug Class
6.7 Rest of Europe Antibiotics Market
6.7.1 Rest of Europe Antibiotics Market by Action Mechanism
6.7.2 Rest of Europe Antibiotics Market by Drug Class
Chapter 7. Company Profiles
7.1 GlaxoSmithKline PLC (GSK)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Johnson and Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Acquisition and Mergers:
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Product Launches and Product Expansions:
7.3.1.2 Approvals:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Recent strategies and developments:
7.4.4.1 Acquisition and Mergers:
7.4.4.2 Product Launches and Product Expansions:
7.5 Bayer AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Acquisition and Mergers:
7.7.5.2 Partnerships, Collaborations, and Agreements:
7.8 Abbott Laboratories
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.10. Eli Lilly and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
TABLE 1 Europe Antibiotics Market, 2016 - 2019, USD Million
TABLE 2 Europe Antibiotics Market, 2020 - 2026, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Antibiotics Market
TABLE 4 Product Launches And Product Expansions– Antibiotics Market
TABLE 5 Approvals– Antibiotics Market
TABLE 6 Acquisition and Mergers– Antibiotics Market
TABLE 7 Europe Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 8 Europe Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 9 Europe Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 10 Europe Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 11 Europe Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 12 Europe Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 13 Europe DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 14 Europe DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 15 Europe RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 16 Europe RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 17 Europe Others Market by Country, 2016 - 2019, USD Million
TABLE 18 Europe Others Market by Country, 2020 - 2026, USD Million
TABLE 19 Europe Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 20 Europe Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 21 Europe Cephalosporin Market by Country, 2016 - 2019, USD Million
TABLE 22 Europe Cephalosporin Market by Country, 2020 - 2026, USD Million
TABLE 23 Europe Penicillin Market by Country, 2016 - 2019, USD Million
TABLE 24 Europe Penicillin Market by Country, 2020 - 2026, USD Million
TABLE 25 Europe Fluoroquinolone Market by Country, 2016 - 2019, USD Million
TABLE 26 Europe Fluoroquinolone Market by Country, 2020 - 2026, USD Million
TABLE 27 Europe Macrolides Market by Country, 2016 - 2019, USD Million
TABLE 28 Europe Macrolides Market by Country, 2020 - 2026, USD Million
TABLE 29 Europe Carbapenem Market by Country, 2016 - 2019, USD Million
TABLE 30 Europe Carbapenem Market by Country, 2020 - 2026, USD Million
TABLE 31 Europe Aminoglycosides Market by Country, 2016 - 2019, USD Million
TABLE 32 Europe Aminoglycosides Market by Country, 2020 - 2026, USD Million
TABLE 33 Europe Sulfonamides Market by Country, 2016 - 2019, USD Million
TABLE 34 Europe Sulfonamides Market by Country, 2020 - 2026, USD Million
TABLE 35 Europe Others Market by Country, 2016 - 2019, USD Million
TABLE 36 Europe Others Market by Country, 2020 - 2026, USD Million
TABLE 37 Europe Antibiotics Market by Country, 2016 - 2019, USD Million
TABLE 38 Europe Antibiotics Market by Country, 2020 - 2026, USD Million
TABLE 39 Germany Antibiotics Market, 2016 - 2019, USD Million
TABLE 40 Germany Antibiotics Market, 2020 - 2026, USD Million
TABLE 41 Germany Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 42 Germany Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 43 Germany Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 44 Germany Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 45 UK Antibiotics Market, 2016 - 2019, USD Million
TABLE 46 UK Antibiotics Market, 2020 - 2026, USD Million
TABLE 47 UK Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 48 UK Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 49 UK Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 50 UK Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 51 France Antibiotics Market, 2016 - 2019, USD Million
TABLE 52 France Antibiotics Market, 2020 - 2026, USD Million
TABLE 53 France Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 54 France Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 55 France Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 56 France Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 57 Russia Antibiotics Market, 2016 - 2019, USD Million
TABLE 58 Russia Antibiotics Market, 2020 - 2026, USD Million
TABLE 59 Russia Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 60 Russia Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 61 Russia Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 62 Russia Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 63 Spain Antibiotics Market, 2016 - 2019, USD Million
TABLE 64 Spain Antibiotics Market, 2020 - 2026, USD Million
TABLE 65 Spain Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 66 Spain Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 67 Spain Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 68 Spain Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 69 Italy Antibiotics Market, 2016 - 2019, USD Million
TABLE 70 Italy Antibiotics Market, 2020 - 2026, USD Million
TABLE 71 Italy Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 72 Italy Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 73 Italy Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 74 Italy Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 75 Rest of Europe Antibiotics Market, 2016 - 2019, USD Million
TABLE 76 Rest of Europe Antibiotics Market, 2020 - 2026, USD Million
TABLE 77 Rest of Europe Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 78 Rest of Europe Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 79 Rest of Europe Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 80 Rest of Europe Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 81 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 82 Key information –Johnson and Johnson
TABLE 83 key information - Merck & Co., Inc.
TABLE 84 Key Information – Pfizer, Inc.
TABLE 85 Key Information – Bayer AG
TABLE 86 Key Information – Novartis AG
TABLE 87 Key Information – Sanofi S.A.
TABLE 88 Key Information – Abbott Laboratories
TABLE 89 key information – F. Hoffmann-La Roche Ltd.
TABLE 90 Key Information – Eli Lilly and Company
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct – 2020, Jul) Leading Players
FIG 5 Recent strategies and developments: Merck & Co., Inc.
FIG 6 Recent strategies and developments: Pfizer, Inc.
FIG 7 Recent strategies and developments: Sanofi S.A.